

CLAIM AMENDMENTS

Please amend the claims as follows:

1-44. (Canceled)

45. (Previously presented) A method for ameliorating the effects of a proliferative and/or inflammatory skin disorder in a mammal, said method comprising contacting the proliferating and/or inflamed skin with an effective amount of a nucleic acid molecule selected from the group consisting of 5'-UCCGGAGCCAGACUU-3' (SEQ ID NO:12); 5'-CACAGUUGCUGCAAG-3' (SEQ ID NO:13); 5'-UCUCCGCUUCCUUUC-3' (SEQ ID NO:14); 5'-AGCCCCCACAGCGAG-3' (SEQ ID NO:15); 5'-GCCUUGGAGAUGAGC-3' (SEQ ID NO:16); 5'-UAACAGAGGUCAGCA-3' (SEQ ID NO:17); 5'-GGAUCAGGGACCAGU-3' (SEQ ID NO:18); 5'-CGGCAAGCUACACAG-5' (SEQ ID NO:19); 5'-GGCAGGCAGGCACAC-3' (SEQ ID NO:20) or chemical modification of any one of said nucleic acid molecules, wherein said modification produces a modified nucleic acid molecule having a length and nucleotide sequence which is the same as the nucleic acid molecule prior to modification, and wherein the nucleic acid molecule or modified nucleic acid molecule is capable of reducing the level of IGF-I receptor in said mammal.

46. (Previously presented) The method according to Claim 45 wherein the mammal is a human.

47-48. (Canceled)

49. (Previously presented) The method according to Claim 45 wherein the proliferative or inflammatory skin disorder is psoriasis, eczema, ichthyosis, pityriasis, rubra, pilaris, serborrhoea, keloids, keratosis, neoplasias, scleroderma, warts, benign growths or cancers of the skin.
50. (Previously presented) The method according to Claim 49 wherein the is psoriasis.
51. (Canceled)
52. (Currently amended) The method according to Claim 45 wherein the nucleic acid molecule is 5'-UCCGGAGCCAGACUU-3' (SEQ ID NO:12) ~~or a modification thereof~~.
53. (Currently amended) The method according to Claim 45 wherein the nucleic acid molecule is 5'-CACAGUUGCUGCAAG-3' (SEQ ID NO:13) ~~or a modification thereof~~.
54. (Currently amended) The method according to Claim 45 wherein the nucleic acid molecule is 5'-UCUCCGCUUCCUUUC-3' (SEQ ID NO:14) ~~or a modification thereof~~.
55. (Currently amended) The method according to Claim 45 wherein the nucleic acid molecule is 5'-AGCCCCCACAGCGAG-3' (SEQ ID NO:15) ~~or a modification thereof~~.
56. (Currently amended) The method according to Claim 45 herein the nucleic acid molecule is 5'-GCCUUGGAGAUGAGC-3' (SEQ ID NO:16) ~~or a modification thereof~~.
57. (Currently amended) The method according to Claim 45 wherein the nucleic acid molecule is 5'-UAACAGAGGUCAGCA-3' (SEQ ID NO:17) ~~or a modification thereof~~.
58. (Currently amended) The method according to Claim 45 wherein the nucleic acid molecule is 5'-GGAUCAGGGACCAGU-3' (SEQ ID NO:18) ~~or a modification thereof~~.

59. (Currently amended) The method according to Claim 45 wherein the nucleic acid molecule is 5'-CGGCAAGCUACACAG-3' (SEQ ID NO:19) ~~or a modification thereof~~.

60. (Currently amended) The method according to Claim 45 wherein the nucleic acid molecule is 5'-GGCAGGCAGGCACAC-3' (SEQ ID NO:20) ~~or a modification thereof~~.

61-63. (Canceled)

64. (Currently amended) A method of ameliorating the effects of psoriasis in a mammal, said method comprising contacting proliferating skin with an effective amount of one or more nucleic acid molecules ~~or~~ selected from the group consisting of 5'-UCCGGAGCCAGACUU-3' (SEQ ID NO:12); 5'-CACAGUUGCUGCAAG-3' (SEQ ID NO:13); 5'-UCUCCGCUUCCUUUC-3' (SEQ ID NO:14); 5'-AGCCCCCACAGCGAG-3' (SEQ ID NO:15); 5'-GCCUUGGAGAUGAGC-3' (SEQ ID NO:16); 5'-UAACAGAGGUCAGCA-3' (SEQ ID NO:17); 5'-GGAUCAGGGACCAGU-3' (SEQ ID NO:18); 5'-CGGCAAGCUACACAG-3' (SEQ ID NO:19); 5'-GGCAGGCAGGCACAC-3' (SEQ ID NO:20) or chemical modification of any one of said nucleic acid molecules, wherein said modification produces a modified nucleic acid molecule having a length and nucleotide sequence which is the same as the nucleic acid molecule prior to modification and wherein said nucleic acid molecule or modified nucleic acid molecule is capable of interacting with mRNA transcribed from an IGF-I gene, an IGF-I receptor gene or a gene encoding an ~~IGFBP~~ IGF binding protein.

65. (Previously presented) The method according to Claim 64 wherein the mammal is a human.

66. (Canceled)

67. (Currently amended) The method according to Claim 64 wherein the nucleic acid molecule is 5'-UCCGGAGCCAGACUU-3' (SEQ ID NO:12) ~~or a modification thereof~~.

68. (Currently amended) The method according to Claim 64 wherein the nucleic acid molecule is 5'-CACAGUUGCUGCAAG-3' (SEQ ID NO:13) ~~or a modification thereof~~.

69. (Currently amended) The method according to Claim 64 wherein the nucleic acid molecule is 5'-UCUCCGCUUCCUUUC-3' (SEQ ID NO:14) ~~or a modification thereof~~.

70. (Currently amended) The method according to Claim 64 wherein the nucleic acid molecule is 5'-AGCCCCACAGCGAG-3' (SEQ ID NO:15) ~~or a modification thereof~~.

71. (Currently amended) The method according to Claim 64 wherein the nucleic acid molecule is 5'-GCCUUGGAGAUGAGC-3' (SEQ ID NO:16) ~~or a modification thereof~~.

72. (Currently amended) The method according to Claim 64 wherein the nucleic acid molecule is 5'-UAACAGAGGUCAGCA-3' (SEQ ID NO:17) ~~or a modification thereof~~.

73. (Currently amended) The method according to Claim 64 wherein the nucleic acid molecule is 5'-GGAUCAGGGACCAGU-3' (SEQ ID NO:18) ~~or a modification thereof~~.

74. (Currently amended) The method according to Claim 64 wherein the nucleic acid molecule is 5'-CGGCAAGCUACACAG-5' (SEQ ID NO:19) ~~or a modification thereof~~.

75. (Currently amended) The method according to Claim 64 wherein the nucleic acid molecule is 5'-GGCAGGCAGGCACAC-3' (SEQ ID NO:20) ~~or a modification thereof~~.

76. (Currently amended) A composition comprising a nucleic acid molecule selected from the group consisting of 5'-UCCGGAGCCAGACUU-3' (SEQ ID NO:12); 5'-CACAGUUGCUGCAAG-3' (SEQ ID NO:13); 5'-AGCCCCCACAGCGAG-3' (SEQ ID NO:15); 5'-GCCUUGGAGAUGAGC-3' (SEQ ID NO:16); 5'-UAACAGAGGUCAGCA-3' (SEQ ID NO:17); 5'-GGAUCAGGGACCAGU-3' (SEQ ID NO:18); 5'-CGGCAAGCUACACAG-5' (SEQ ID NO:19); 5'-GGCAGGCAGGCACAC-3' (SEQ ID NO:20) or chemical modification of any one of said nucleic acid molecules, wherein said modification produces a modified nucleic acid molecule having a length and nucleotide sequence which is the same as the nucleic acid molecule prior to modification, and wherein said nucleic acid molecule or modified nucleic acid molecule is capable of reducing the level of IGF-I receptor in a mammal said composition further comprising one or more pharmaceutically acceptable carriers and/or diluents.

77. (Previously presented) The composition according to Claim 76 wherein the mammal is a human.

78. (Canceled)

79. (Currently amended) ~~The composition according to Claim 76 wherein the nucleic acid molecule is~~ A composition comprising a nucleic acid molecule consisting essentially of 5'-UCCGGAGCCAGACUU-3' (SEQ ID NO:12) or a modification thereof or chemical modification of any one of said nucleic acid molecules, wherein said modification produces a modified nucleic acid molecule having a length and nucleotide sequence which is the same as the nucleic acid molecule prior to modification, and wherein said nucleic acid molecule or modified

nucleic acid molecule is capable of reducing the level of IGF-I receptor in a mammal said composition further comprising one or more pharmaceutically acceptable carriers and/or diluents.

80. (Currently amended) The composition according to Claim 76 wherein the nucleic acid molecule is 5'-CACAGUUGCUGCAAG-3' (SEQ ID NO:13) ~~or a modification thereof.~~

81. (Canceled)

82. (Currently amended) The composition according to Claim 76 wherein the nucleic acid molecule is 5'-AGCCCCACAGCGAG-3' (SEQ ID NO:15) ~~or a modification thereof.~~

83. (Currently amended) The composition according to Claim 76 wherein the nucleic acid molecule is 5'-GCCUUGGAGAUGAGC-3' (SEQ ID NO:16) ~~or a modification thereof.~~

84. (Currently amended) A composition according to Claim 76 wherein the nucleic acid molecule is 5'-UACAGAGGUCAGCA-3' (SEQ ID NO:17) ~~or a modification thereof.~~

85. (Currently amended) The composition according to Claim 76 wherein the nucleic acid molecule is 5'-CGGCAAGCUACACAG-5' (SEQ ID NO:19) ~~or a modification thereof.~~

86. (Currently amended) The composition according to Claim 76 wherein the nucleic acid molecule is 5'-GGCAGGCAGGCACAC-3' (SEQ ID NO:20) ~~or a modification thereof.~~

87. (Currently amended) The composition according to Claim 76 wherein the nucleic acid molecule is 5'-GGAUCAGGGACCAGU-3' (SEQ ID NO:18) ~~or a modification thereof.~~